Clinical Trial Update: Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension [Phase 3]

View source ↗

Summary

Open-label extension of a Phase 3 trial evaluating Enlicitide Decanoate (MK-0616) for hypercholesterolemia, with ACTIVE_NOT_RECRUITING status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Enlicitide Decanoate (Enlicitide Decanoate)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hypercholesterolemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING